Cystic Fibrosis News and Research RSS Feed - Cystic Fibrosis News and Research

Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus.

Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.

In the airways, this mucus causes a persistent cough, wheezing, breathlessness, and repeated lung infections. In the digestive tract, the tubes that carry digestive enzymes from the pancreas into the small intestine become blocked, preventing the proper absorption of food nutrients. This can lead to poor weight gain, intestinal blockage (particularly in newborns), and foul-smelling, greasy stools.

There is no cure for cystic fibrosis, so treatment aims to ease symptoms and make the condition easier to live with. Bronchodilators may be used to help expand the airways, antibiotics to treat chest infections and physiotherapy can help expel mucus from the lungs.
The condition is most common in white people of northern European descent and is estimated to occurs in 1 in every 2,500 babies born in the UK, where babies are screened at birth for cystic fibrosis as part of the National Health Service newborn screening programme.
Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI). [More]
Unique ability helps prolific bacterium to afflict humans, animals and even plants

Unique ability helps prolific bacterium to afflict humans, animals and even plants

New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism -- a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment. [More]
TSRI study examines body’s own response against chronic protein misfolding

TSRI study examines body’s own response against chronic protein misfolding

“Protein misfolding” diseases such as cystic fibrosis and Alzheimer’s may be seriously exacerbated by the body’s own response against that misfolding, according to a new study led by scientists at The Scripps Research Institute. [More]

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014. [More]
Salivary mucins protect teeth from cariogenic bacterium

Salivary mucins protect teeth from cariogenic bacterium

Salivary mucins, key components of mucus, actively protect the teeth from the cariogenic bacterium, Streptococcus mutans, according to research published ahead of print in Applied and Environmental Microbiology. The research suggests that bolstering native defenses might be a better way to fight dental caries than relying on exogenous materials, such as sealants and fluoride treatment, says first author Erica Shapiro Frenkel, of Harvard University, Cambridge, MA. [More]
Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases. [More]
Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan Holdings Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, and Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, today announce that they have entered into a research collaboration in the area of osteoarthritis pain. [More]
Antibiotic-resistant bacteria share resources to cause chronic infections, show studies

Antibiotic-resistant bacteria share resources to cause chronic infections, show studies

Antibiotic-resistant bacteria can share resources to cause chronic infections, Vanderbilt University investigators have discovered. [More]
Major scientific breakthrough in understanding retinal degenerative diseases that cause blindness

Major scientific breakthrough in understanding retinal degenerative diseases that cause blindness

An important scientific breakthrough by a team of IRCM researchers led by Michel Cayouette, PhD, is being published today by The Journal of Neuroscience. The Montréal scientists discovered that a protein found in the retina plays an essential role in the function and survival of light-sensing cells that are required for vision. [More]

Tannic acid may help ease impact of bacterial lung infections in CF patients

By screening over 2,000 approved drugs and natural products, scientists have shown that tannic acid may help ease the impact of bacterial lung infections in cystic fibrosis patients. [More]
International Biophysics files patent protection for revolutionary AffloVest

International Biophysics files patent protection for revolutionary AffloVest

International Biophysics Corporation of Austin, Texas announces its filing of U.S. patent protection for its revolutionary AffloVest. The company has also recently confirmed exclusive ownership rights concerning the manufacture, sale and distribution of the AffloVest in its markets. [More]
Childhood eating disorders could have underlying psychological issues, researchers warn

Childhood eating disorders could have underlying psychological issues, researchers warn

Researchers at the University of Montreal and its affiliated CHU Sainte-Justine children's hospital are warning parents that difficult eaters could have underlying psychological issues, as they have found that restrictive behaviours can appear before puberty. [More]
IRCM researchers discover mechanism that promotes progression of medulloblastoma

IRCM researchers discover mechanism that promotes progression of medulloblastoma

Scientists at the IRCM discovered a mechanism that promotes the progression of medulloblastoma, the most common brain tumour found in children. The team, led by Fr-d-ric Charron, PhD, found that a protein known as Sonic Hedgehog induces DNA damage, which causes the cancer to develop. [More]
Allakos secures additional $10M investment to expand its development portfolio

Allakos secures additional $10M investment to expand its development portfolio

Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody. [More]
Leading Cystic Fibrosis experts call for greater research on antibacterial resistance

Leading Cystic Fibrosis experts call for greater research on antibacterial resistance

World leading Cystic Fibrosis experts, from Queen's University Belfast, have called for greater research to address the major concern of antibacterial resistance. [More]
Study demonstrates longer-term benefits of Lung Flute for COPD patients

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute-, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the U.S. [More]

US children with cystic fibrosis have better lung function compared to UK counterparts

There are significant differences in the lung function of children and young adults in the United States (US) who have cystic fibrosis compared with those in the United Kingdom (UK). [More]

Sheffield Teaching Hospitals NHS Foundation Trust nominated twice for Health Service Journal Awards

SHEFFIELD Teaching Hospitals NHS Foundation Trust has been nominated twice for outstanding ideas improving patient care in the Health Service Journal Awards 2014 – one of the most coveted awards in healthcare. [More]
New method helps reveal secret dance of proteins

New method helps reveal secret dance of proteins

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners as they degrade and build up the human body, brain and nervous system. [More]

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF). [More]